Protagonist Therapeutics PTGX Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's business segments — allocated share based compensation expense?
- Protagonist Therapeutics (PTGX) reported business segments — allocated share based compensation expense of $14.52M in Q1 2026.
- How has Protagonist Therapeutics's business segments — allocated share based compensation expense changed year-over-year?
- Protagonist Therapeutics's business segments — allocated share based compensation expense increased by 5.2% year-over-year, from $13.8M to $14.52M.
- What is the long-term trend for Protagonist Therapeutics's business segments — allocated share based compensation expense?
- Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — allocated share based compensation expense has grown at a 23.8% compound annual growth rate (CAGR), from $24.2M to $45.97M.
- What does business segments — allocated share based compensation expense mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees and directors across the organization. It is a critical component of total compensation that aligns the interests of the workforce with long-term shareholder value. Investors monitor this to understand the dilution impact and the total cost of talent acquisition and retention.